EP2311454 treatment for atopic dermatitis: therapeutic efficiency in patients and anti-inflammatory in vitro

I Umbert
2017 Clinical Dermatology  
Background. Atopic Dermatitis (AD) is a common, chronic skin disorder caused by complex genetic, immunological, and environmental interactions. The current standard treatments for AD are improvable with a low efficiency, particularly in severe cases. Using well characterized molecules the "Ignacio Umbert Dermatology Institute" (IUDI) has developed topical treatments differentiated from the standards (European patent number EP2311454). Objective. Evaluate the therapeutic efficacy of EP2311454
more » ... acy of EP2311454 treatment in AD patients and its antiinflammatory effect in vitro. Materials and methods. Using a cellular model for human macrophages (THP-1 cell line) the principal components of EP2311454 treatment was evaluated. Expression of proinflammatory cytokines was measured through RNA quantification and ELISA technique. Therapeutically EP231154 treatment was tested in forty three AD patients and SCORing Atopic Dermatitis (SCORAD) and Dermatology Quality of Life Index (DLQI) was evaluated before and after the treatment. Results. The effect was significantly anti-inflammatory towards IL6 and COX2. The therapeutic efficacy was demonstrated by obtaining a reduction of initial SCORAD levels in the 97,7% of patients besides EP2311454 treatment reduces DLQI significantly. Conclusions. Clinically, EP2311454 treatment is effective, especially in severe cases, getting a reduction of 80% initial levels at the end of the evaluation period. Moreover, the effect was detected from the first week.
doi:10.11138/cderm/2017.5.1.005 fatcat:dwtqxxminbh2nl2vj4vs4aikgy